The Pharma Data

JANUARY 4, 2021

. “This is a compelling first step in defining a potential relationship between maternal diet and allergy risk,” said Dr. Peter Lio, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, in Chicago.

Allergies 52

Allergies Doctors Doctor Dermatology 52

Pfizer

JANUARY 27, 2023

That is why, for more than two decades, Pfizer has proudly joined researchers, global health partners and dozens of governments in efforts to eliminate trachoma,” said Caroline Roan, Senior Vice President, Global Health & Social Impact, Pfizer. “We Disclosure Notice The information contained in this statement is as of January [30], 2023.

Bacteria 75

Bacteria Medicine Containment Manufacturing 75

The Pharma Data

FEBRUARY 22, 2022

Next-generation respiratory inhalers Most patients with asthma and chronic obstructive pulmonary disease (COPD) need inhaled medicines 2 and many make use of pressurised metered dose inhalers (pMDIs) 2 which contain small quantities of a type of GHG which acts as the propellant to deliver the medicine into the lungs.

Development 52

Development Medicine Containment Dermatology 52

XTalks

DECEMBER 20, 2023

Novo Nordisk’s GLP-1 weight loss-specific drug Wegovy (semaglutide) has been facing similar shortages, as it contains the same active ingredient as Ozempic. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

The Pharma Data

AUGUST 22, 2021

a CheckMate -274 primary investigator and Professor of Medicine, Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, and Associate Director for Translational Research at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Galsky,* M.D.,

Drugs 52

Drugs HR FDA Approval Trials 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

The Pharma Data

NOVEMBER 4, 2020

Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

XTalks

JUNE 10, 2021

Researchers at Massachusetts Institute of Technology (MIT) have designed the world’s first digital fabric fiber that contains digital devices which can sense, analyze and store health data, and use it to infer a person’s activity and state of health. Related: Google Launches AI-Based Dermatology Assist Tool.

Research 111

Research Development Containment Engineer 111

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14. IR main line: Tel.: +33

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

Bioengineer

JULY 20, 2021

Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam® 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam® 10% at the minimum infusion rate practicable.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

The Pharma Data

AUGUST 17, 2021

Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. GSK is responsible for the ongoing research, development, commercialization, and manufacture of each of these Products under the Agreement. Immune-Mediated Dermatologic Adverse Reactions.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

MAY 18, 2021

There was also a positive effect on research and development expenses that came partly from the proportionate recognition of proceeds from the sale of a priority review voucher in the United States. ? The performance remained ahead of competition with growth momentum in the Dermatology and Nutritionals categories, with business up by 6.6

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JANUARY 26, 2021

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The company assumes no obligation to update any information contained herein.”. Dr. Reddy’s operates in markets across the globe. For more information, log on to: www.drreddys.com.

Life Science 40

Life Science Production Marketing Dermatology 40

The Pharma Data

DECEMBER 15, 2020

We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need. Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

FDA Approval 52

FDA Approval Development Production Marketing 52

The Pharma Data

JULY 11, 2021

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. percent (-100; 852.8), and the median reduction was 97.7 Interactions.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

MARCH 3, 2021

Symbicort (budesonide/formoterol) is a combination formulation containing budesonide, an inhaled corticosteroid that treats underlying inflammation, and formoterol, a long-acting beta2-agonist bronchodilator with a fast onset of action, in a single inhaler.

Dermatology 52

Dermatology Drug Delivery Medicine Containment 52

The Pharma Data

OCTOBER 26, 2020

They need additional treatment options that alleviate the symptoms most important to them,” said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. DISCLOSURE NOTICE: The information contained in this release is as of October 27, 2020. Dermatology.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Medicine 40

The Pharma Data

NOVEMBER 12, 2020

Information from the World Health Organization indicates that over the past 10 years, reports of suicidal ideation among young men using the drug have increased, rising significantly after 2012, the researchers said. 11 in JAMA Dermatology. Its use was later extended to treat male-pattern baldness. The report was published online Nov.

Dermatology 52

Dermatology Drugs Packaging Packaging 52

The Pharma Data

JANUARY 13, 2021

Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. Brilacidin antiviral research to date has been limited to laboratory-based experiments.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

JULY 8, 2021

KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. 1) as determined by an FDA-approved test.

FDA Approval 52

FDA Approval Containment Trials Genome 52

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. 1] as determined by an FDA-approved test.

HR 52

HR FDA Approval Containment Genome 52

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. It contains the antiviral medications nirmatrelvir and ritonavir. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022. and $16,382.51

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 24, 2021

It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. VP-102 is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidim delivered by way of a single-use applicator.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

APRIL 4, 2023

Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

JULY 23, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Dermatologic Adverse Reactions OPDIVO can cause immune-mediated rash or dermatitis.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. Disclosure Notice: The information contained in this release is as of September 15, 2020.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Adakveo sales reached USD 37 million. Sandoz sales declined -13% (cc, -9% USD), with Retail -18% (cc) and Biopharmaceuticals growing +7% (cc).

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MARCH 11, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Dermatologic Adverse Reactions. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Genome Genomics 52

Pfizer

OCTOBER 28, 2022

With a focus on Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars. DISCLOSURE NOTICE: The information contained in this release is as of October 28, 2022.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. Immune-Mediated Skin and Dermatologic Adverse Reactions. While GEJ cancer has a lower prevalence than gastric cancer, it continues to rise.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. Immune-Mediated Skin and Dermatologic Adverse Reactions. At Bristol Myers Squibb, patients are at the center of everything we do.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 13, 2020

It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler. Preclinical research showed SAR440340 blocked several markers of both types of inflammation.

Antibody 40

Antibody Medicine Trials Development 40